1. Ohta Y, Tsuchihashi T, Arakawa K, Onaka U, Ueno M. Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatient clinic in Fukuoka, Japan. Hypertens Res 2007; 30: 1077-82.
2. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men; The Osaka Health Survey. J Hypertens 2001; 19: 1209-15.
3. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertension Res 2001; 24: 691-7.
4. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-64.
5. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-21.
6. Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1018-29.
7. Ohtahara A, Hisatome I, Yamamoto Y, Furuse M, Sonoyama K, Furuse Y, et al. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. J Hypertens 2001; 19: 575-82.
8. Nakamura M, Anzai N, Jutabha P, Sato H, Sakurai H, Ichida K. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters. J Pharmacol Sci 2010; 114: 115-8.
9. Sugihara S, Hisatome I, Kuwabara M, Niwa K, Maharani N, Kato M, et al. Depletion of uric acid due to SLC22A12 (URAT1) lossof-function mutation causes endothelial dysfunction in hypouricemia. Circ J 2015; 79: 1125-32.
10. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-8.
11. Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 2005; 20: 1103-9.
12. Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol 2014; 6: 79-86.
13. Li X, Chen XD, Li ZX. The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease. Zhonghua Nei Ke Za Zhi 2011; 50: 1034-8.
14. Hisatome I, Ogino K, Kotake H, Ishiko R, Saito M, Hasegawa J, et al. Cause of persistent hypouricemia in outpatients. Nephron 1989; 51: 13-6.
15. Hisatome I, Kato T, Miyakoda H, Takami T, Abe T, Tanaka Y, et al. Renal hypouricemia with both drug-insensitive secretion and defective reabsorption of urate: a novel type of renal hypouricemia. Nephron 1993; 64: 447-51.
16. Miyazaki S, Hamada T, Hirata S, Ohtahara A, Mizuta E, Yamamoto Y, et al. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. Clin Exp Hypertens 2014; 36: 447-53.
17. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996; 9: 746-52.
18. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670-1.
19. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.
20. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21: 1157-62.
21. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447- 52.
22. Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 2006; 20: 45-50.
23. Derosa G, Salvadeo SA. Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. Integr Blood Press Control 2010; 3: 21-30.